Skip Navigation



Annals of Oncology Advance Access published online on May 10, 2006
Annals of Oncology, doi:10.1093/annonc/mdl083
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/7/1146    most recent
mdl083v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Palmieri, S.
Right arrow Articles by Ferrara, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Palmieri, S.
Right arrow Articles by Ferrara, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology
Received January 10, 2006
Revised March 13, 2006
Accepted March 14, 2006

original article

An antecedent diagnosis of refractory anemia with excess blasts has no prognostic relevance in acute myeloid leukemia of older adult patients

S. Palmieri 1, A. M. D'Arco 2, M. Celentano 1, G. Mele 1, C. Califano 2, F. Pollio 1, M. R. D'Amico 1, and F. Ferrara 1 *

1 Division of Hematology and Stem Cell Transplantation Unit, Cardarelli Hospital, Naples
2 Division of Onco-Hematology, Umberto I Hospital, Nocera Inferiore, Italy

* To whom correspondence should be addressed.
F. Ferrara, E-mail: felicettoferrara{at}katamail.com


  Abstract

Background: Conflicting results have been reported about the prognostic relevance of antecedent myelodysplastic syndrome (MDS) in acute myeloid leukemia (AML) of older adults.

Patients and methods: Data from 87 intensively treated AML patients (median age 69 years) were analyzed, with the aim of comparing therapeutic results and toxicity between de novo and AML secondary to a previous MDS (s-AML). Rate of CD34+ cells mobilization and feasibility of autologous stem cell transplantation (ASCT) were also compared.

Results: Complete remission rate, death in induction and primary resistance were not statistically different between the two groups. Median time for neutrophil recovery was similar, while s-AML patients required a longer time for platelet recovery (P = 0.04). There was no difference as to eligibility for consolidation as well as for mobilization and feasibility of ASCT. S-AML had negligible impact on overall survival (OS) and disease-free survival (DFS). In the multivariate analysis the only parameter significantly related to either OS or DFS duration was adverse karyotype (P = 0.02 and 0.04, respectively).

Conclusions: A diagnosis of s-AML does not represent a clinically relevant prognostic factor in elderly AML patients treated with aggressive therapy. Furthermore, s-AML patients can be mobilized and autografted with comparable results as opposed to de novo cases.

Keywords: acute myeloid leukemia; elderly patients; antecedent MDS; prognostic relevance.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.